RY 134.95 -0.5234% TD 78.09 -0.2555% SHOP 94.89 -1.597% CNR 177.13 0.1017% ENB 46.485 -1.2428% CP 117.32 -1.0375% BMO 127.71 -0.3433% TRI 210.4 0.243% CNQ 106.69 -2.1552% BN 53.53 -1.1084% ATD 76.02 0.7822% CSU 3608.0 0.7343% BNS 65.45 -1.4456% CM 65.68 -0.7105% SU 51.21 -1.3675% TRP 49.44 -0.5831% NGT 53.21 -0.1689% WCN 227.74 -1.1073% MFC 31.625 -1.0172% BCE 44.48 0.5652%

Antibe Therapeutics Inc.

Healthcare CA ATE

0.295CAD
-(-%)

Last update at 2024-04-12T13:30:00Z

Day Range

0.290.29
LowHigh

52 Week Range

0.431.23
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Income before tax -19.29100M -25.25000M -24.73400M -19.34900M -12.68195M
Minority interest - - - - -
Net income -19.47500M -25.05500M -26.58900M -19.34200M -12.81607M
Selling general administrative 9.24M 10.96M 11.19M 8.77M 7.86M
Selling and marketing expenses - 0.21M 2.72M 3.79M 3.52M
Gross profit - - 3.55M 3.89M 3.55M
Reconciled depreciation 0.00000M 0.10M 0.48M 0.57M 0.42M
Ebit -20.54600M -25.52900M -24.26200M -17.31700M -12.25166M
Ebitda -19.28300M -25.14800M -23.73200M -16.64600M -11.83544M
Depreciation and amortization - 0.38M 0.53M 0.67M 0.42M
Non operating income net other - - - - -
Operating income -20.54600M -25.52900M -24.26200M -17.31700M -12.18801M
Other operating expenses - 25.53M 33.98M 27.30M 21.73M
Interest expense 0.00800M 0.00800M 0.24M 0.50M 0.43M
Tax provision - 0.00000M 0.00000M -0.00700M 0.13M
Interest income 1.35M 0.28M 0.05M 0.29M 0.37M
Net interest income 1.34M 0.27M -0.18400M -0.40100M -0.39888M
Extraordinary items - 0.19M -1.56700M -0.29200M -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.19500M 1.85M -0.00700M 0.13M
Total revenue 0.00000M 0.00000M 9.71M 9.99M 9.54M
Total operating expenses 20.55M 25.53M 27.81M 21.21M 15.74M
Cost of revenue - - 6.16M 6.10M 5.99M
Total other income expense net -0.09000M 0.28M -0.47200M -2.03200M -0.49394M
Discontinued operations -0.18400M 0.19M -2.44800M -0.29200M -0.29200M
Net income from continuing ops -19.29100M -25.25000M -24.73400M -19.34200M -12.81607M
Net income applicable to common shares -19.47500M -25.06000M -26.30100M -19.34200M -12.81600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Total assets 70.56M 89.16M 81.74M 13.84M 14.82M
Intangible assets 26.35M 26.35M 0.87M 1.77M 2.43M
Earning assets - - - - -
Other current assets 0.92M 5.44M 2.36M 0.18M 0.18M
Total liab 30.39M 32.33M 31.48M 10.06M 7.38M
Total stockholder equity 40.17M 56.83M 50.26M 3.78M 7.44M
Deferred long term liab 1.28M 1.28M 1.28M 0.24M 0.24M
Other current liab - 4.69M 1.28M 5.26M 2.91M
Common stock 141.49M 139.55M 111.57M 49.67M 36.99M
Capital stock 141.49M 139.55M 111.57M 49.67M 36.99M
Retained earnings -130.49100M -111.01600M -85.95600M -59.67300M -40.33159M
Other liab 27.63M 27.63M 27.63M 2.40M 2.40M
Good will - - - 0.00000M 1.28M
Other assets 2.66M 1.44M 1.46M 0.26M 0.26M
Cash 6.75M 34.81M 71.97M 6.18M 5.99M
Cash and equivalents - 34.81M 71.97M - -
Total current liabilities 2.76M 4.69M 3.74M 7.59M 2.91M
Current deferred revenue - - - - -
Net debt - -34.80700M -71.73500M -3.78400M -3.92059M
Short term debt - 0.00000M 0.13M 2.33M 0.03M
Short long term debt - - - 2.22M -
Short long term debt total - - 0.24M 2.40M 2.07M
Other stockholder equity 10.26M 28.30M 24.65M 13.77M 10.79M
Property plant equipment - 0.00000M 0.31M 0.30M 0.18M
Total current assets 41.55M 61.36M 79.10M 11.51M 10.56M
Long term investments - - - 0.00000M 0.10M
Net tangible assets 13.81M 30.48M 49.40M 2.01M 3.72M
Short term investments 32.14M 20.00M 0.03M 0.03M 0.03M
Net receivables 0.74M 1.12M 2.58M 1.69M 1.57M
Long term debt - - - 0.00000M 2.07M
Inventory 0.78M 0.57M 2.16M 3.42M 2.80M
Accounts payable 2.76M 2.82M 2.33M 3.98M 2.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - 0.02M -0.00468M
Additional paid in capital - - - - -
Common stock total equity - - - 49.67M 36.99M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 1.44M 1.46M 0.26M 0.26M
Deferred long term asset charges - - - - -
Non current assets total 29.02M 27.79M 2.64M 2.33M 4.26M
Capital lease obligations - 0.00000M 0.24M 0.18M -
Long term debt total - 0.00000M 0.10M 0.07M 2.07M
Breakdown 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Type yearly yearly yearly yearly yearly
Date 2023-03-31 2022-03-31 2021-03-31 2020-03-31 2019-03-31
Investments -12.13700M -19.97500M -19.97500M 0.10M -0.25740M
Change to liabilities 0.04M 0.93M 23.77M 2.35M 1.01M
Total cashflows from investing activities -11.82700M -20.22000M -0.26400M 0.10M -0.25700M
Net borrowings -0.07900M -0.15200M -2.41100M -0.18800M 0.68M
Total cash from financing activities 0.08M -0.02600M 66.16M 12.00M 9.59M
Change to operating activities -0.21900M 1.52M -3.23300M -0.00700M -0.21900M
Net income -19.47500M -25.06000M -24.73400M -19.34200M -12.81607M
Change in cash -28.05200M -37.16600M 65.79M 0.19M 2.27M
Begin period cash flow 34.81M 71.97M 6.18M 5.99M 3.73M
End period cash flow 6.75M 34.81M 71.97M 6.18M 5.99M
Total cash from operating activities -16.30500M -16.92000M -0.10500M -11.93500M -7.05570M
Issuance of capital stock - 0.00000M 69.11M 8.05M 5.93M
Depreciation 0.00000M 0.10M 0.48M 0.57M 0.42M
Other cashflows from investing activities -11.81800M -20.21100M -0.26400M 0.10M -0.10000M
Dividends paid - - - - -
Change to inventory -0.23900M -0.09900M 0.53M -0.62100M 0.30M
Change to account receivables 0.44M 0.29M -1.35600M -0.03900M -0.18576M
Sale purchase of stock 0.00000M 0.13M 74.18M 13.12M 9.76M
Other cashflows from financing activities 0.16M 0.13M -0.54500M 4.14M 4.95M
Change to netincome 3.14M 5.54M 5.85M 5.14M 4.42M
Capital expenditures 0.00900M 0.00900M 0.00900M 0.00200M 0.16M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.22800M 2.50M 19.66M 1.69M 2.23M
Stock based compensation 2.81M 5.52M 3.99M 3.38M 2.99M
Other non cash items -0.01400M 0.02M 0.50M 1.77M 0.13M
Free cash flow -16.31400M -16.92900M -0.10500M -11.93700M -7.21310M

Fundamentals

  • Previous Close 0.29
  • Market Cap48.43M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.44700M
  • Revenue TTM9.71M
  • Revenue Per Share TTM0.20
  • Gross Profit TTM 3.55M
  • Diluted EPS TTM-0.35

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATE
Antibe Therapeutics Inc.
- -% 0.29 - - 3.07 1.68 0.18 0.26
FRX
Fennec Pharmaceuticals Inc
-0.34 2.34% 14.20 - 33.33 29.10 84.57 30.47 -23.3985
SVA
Sernova Corp
0.01 2.15% 0.47 - - - 7.95 -4.4095
EPRX
Eupraxia Pharmaceuticals Inc
-0.05 1.35% 3.65 - - - 8.40 -3.9163
TH
Theratechnologies Inc.
-0.07 3.70% 1.82 - 55.25 1.64 19.46 2.23 -11.7353

Reports Covered

Stock Research & News

Profile

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Antibe Therapeutics Inc.

15 Prince Arthur Avenue, Toronto, ON, Canada, M5R 1B2

Key Executives

Name Title Year Born
Mr. Daniel Marcel Legault J.D., L.L.B. Pres, CEO, Sec. & Director 1958
Dr. John Lawrence Wallace M.B.A., M.Sc., MBA, MSc, Ph.D. Founder & Vice Chair 1957
Mr. Alain Wilson M.B.A., MBA Chief Financial Officer NA
Mr. Scott Curtis C.F.A., M.Eng Chief Operating Officer NA
Dr. David James Vaughan Ph.D. Chief Devel. Officer 1950
Dr. Joseph Stauffer D.O., M.B.A. Chief Medical Officer 1966
Dr. Ana Stegic Director of Clinical Operations NA
Ms. Christina Cameron B.B.A. VP of Investor Relations NA
Mr. Philip Stern VP of Communications NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).